Additionally, the effectiveness of single-agent penpulimab-kcqx was determined in Study AK105-202. The study included 125 patients with unresectable or metastatic non-keratinizing NPC who had disease ...

The FDA has approved penpulimab-kcqx, in combination with either cisplatin or carboplatin and gemcitabine, or as a single agent, for metastatic NPC.

References: Coherus and Junshi Biosciences announce FDA approval of Loqtorzi™ (toripalimab-tpzi) in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

Efficacy of toripalimab as a single agent was evaluated in the POLARIS-02 study in 172 patients with unresectable or metastatic nasopharyngeal carcinoma who had received prior platinum-based ...

The single-agent approval is based off findings from the POLARIS-02 trial, which involved 172 patients with unresectable (disease that is unable to be removed via surgery) or metastatic nasopharyngeal ...

Phase II study of gemcitabine single agent for patients with advanced nasopharyngeal carcinoma (NPC) who failed to first line platinum-based chemotherapy No significant financial relationships to ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx ...

Gemcitabine/cisplatin induction chemo significantly improved outcomes in locally advanced nasopharyngeal carcinoma in a trial conducted in China. News & Perspective Drugs & Diseases ...